Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 3/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 8/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | KIT | P10721 | 2/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23996092 | 0.96 | KIT (0.39) | TYK2PDE4DCHRM4MAOAMAOB | |
| SCHEMBL23996101 | 0.94 | TYK2 (0.39) | TYK2PDE4DCHRM4KITMAPK14 | |
| SCHEMBL23996106 | 0.93 | TYK2 (0.39) | TYK2PDE4DCHRM4KITMAPK14 | |
| SCHEMBL23996097 | 0.89 | KIT (0.41) | TYK2PDE4DCHRM4KITMAPK14 | |
| SCHEMBL23996107 | 0.89 | TYK2 (0.41) | TYK2PDE4DCHRM4KITMAPK14 | |
| SCHEMBL23996095 | 0.84 | RIPK1 (0.41) | TYK2PDE4DKITMAPK14 | |
| SCHEMBL23996103 | 0.84 | KIT (0.41) | TYK2PDE4DCHRM4KITMAPK14 | |
| SCHEMBL23996109 | 0.82 | TYK2 (0.40) | TYK2PDE4DKITMAPK14 | |
| SCHEMBL23996108 | 0.81 | TYK2 (0.40) | TYK2PDE4DKITMAPK14 | |
| SCHEMBL19578155 | 0.77 | TYK2 (0.36) | TYK2PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11168087-B2 | Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders | Bial—R&D Investments, S.A. (PT) | 2021-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11168087-B2 | Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders | GBA1, GBA2, GALC | TYK2 873/4885PDE4D 482/4885CHRM4 1589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.